Vistin Pharma — AGM Information 2020

May 19, 2020

PROTOKOLL FRA ORDINÆR GENERALFORSAMLING	MINUTES FROM ANNUAL GENERAL MEETING
1	ΙN
VISTIN PHARMA ASA	VISTIN PHARMA ASA*
Ordinær generalforsamling i Vistin Pharma ASA ("Vistin	The annual general meeting in Vistin Pharma ASA
Pharma" eller "Selskapet") ble avholdt tirsdag 19. mai 2020 kl. 13.00 som et digitalt møte, via Skype.	("Vistin Pharma" or "the Company") was held May 19, 2020 at 1300 hrs (CET) as a digital meeting, through
	Skype.
1. Åpning av møtet og registrering av deltakende	1. Opening of the meeting and registration of
aksjonærer	participating shareholders
Styreleder Ole Enger åpnet møtet.	The Chairman, Ole Enger, opened the meeting.
Tilstede var totalt 11 585 396 aksjer, herav 11 317 322	Present were in total 11 585 396 shares, including
aksjer representert ved fullmakt. Således var ca. 26,1% av Selskapets samlede aksjekapital representert på	11 317 322 shares represented by proxy. Thus, approximately 26.1% of the Company's total share
generalforsamlingen.	capital was represented at the general meeting.
2. Valg av møteleder og person til å signere	2. Election of meeting Chairman and a person to
protokollen sammen med møteleder	co-sign the minutes
Følgende beslutning ble fattet:	The following resolution was passed:
"Ole Enger velges til møteleder. Alexander Karlsen velges til å medundertegne protokollen."	"Ole Enger is elected to chair the meeting. Alexander Karlsen is elected to co-sign the minutes."
3. Godkjennelse av innkalling og saker til	3. Approval of the notice of the meeting and the
behandling	agenda
Det fremkom ingen innsigelser mot innkallingen og	There were no objections to the notice and the agenda,
dagsordenen, og følgende beslutning ble fattet:	and the following resolution was passed:
"Innkalling og dagsorden godkjennes".	"The notice of and agenda for the meeting are
	approved."
4. Godkjennelse av årsregnskap og årsberetning	4. Approval of annual financial statement and the
for 2019	Directors' report for 2019
Følgende vedtak ble fattet:	The following resolution was passed:
"Generalforsamlingen godkjenner årsregnskapet samt	"The General Meeting approves the Annual Financial
styrets beretning for 2019. Utbytte til aksjeeierne fastsettes	Statements and the Directors' Report for 2019. Dividends
til NOK 1 pr aksje, og planlegges å utdeles som en tilbakebetaling av innbetalt kapital. Utbyttet vil tilfalle de som	payable to shareholders is set at NOK 1 per share, and is planned to be distributed as a repayment of paid-in capital.
er aksjeeiere pr 19. mai 2020, eks dato 20. mai 2020.	The dividend will be payable to the shareholders as of 19 May
Utbetaling av utbytte forventes å skje rundt den 5. juni 2020.	2020, ex date 20 May 2020. The payment of dividend is
	expected to take place around 5 June 2020.
5. Honorar til styrets og valgkomitéens	5. Remuneration for the board of directors and the
medlemmer	election committee
Følgende beslutning ble fattet:	The following resolution was passed:
"Innstillingen fra valgkomiteen godkjennes. Honoraret til	"The recommendation from the Election Committee is
aksjonærvalgte styremedlemmer for perioden fra den ordinære general-forsamlingen i 2020 til den ordinære	approved. The remuneration to shareholder-elected board members for the period from the annual general meeting of
general-forsamlingen i 2021 til styrets leder, og styrets	2020 to the annual general meeting of 2021 for the Chairman
medlemmer skal være:	of the Board and Board members:

NOK 250 000 Styrets leder Andre styremedlemmer NOK 200 000	Chairman of the Board NOK 250,000 NOK 200,000 Other Board members
Honoraret til styremedlemmer valgt av ansatte for perioden fra den ordinære generalforsamlingen i 2020 til den ordinære generalforsamlingen i 2021 skal være NOK 125 000.	The remuneration to employee-elected board members for the period from the annual general meeting of 2020 to the annual general meeting of 2021 shall be NOK 125,000.
Honoraret til valgkomiteen for perioden fra den ordinære ordinære generalforsamlingen 2020 til den Ť generalforsamlingen i 2021 fastsettes til:	The remuneration to the Election Committee for the period from the annual general meeting in 2020 to the annual general meeting in 2021 shall be:
Leder i valgkomiteen NOK 15 000 NOK 10 000" Medlem i valgkomiteen	Chairman of the Committee NOK 15,000 NOK 10,000" Members of the Committee
6. Honorar til revisor	6. Auditor's remuneration
Følgende vedtak ble fattet:	The following resolution was passed:
"Generalforsamlingen godkjenner revisors honorar for revisjonen av årsregnskapet til Vistin Pharma ASA for 2019 etter regning."	"The general meeting approves the auditor's remuneration for audit of the Annual Financial Statements of Vistin Pharma ASA for the financial year of 2019 in accordance with invoice."
7. Styrets erklæring om fastsettelse av lønn og annen godtgjørelse til ledende ansatte	7. The Board's statement regarding determination of salary and other compensation to leading employees
Styrets erklæring om lederlønnsfastsettelse i henhold til allmennaksjeloven § 6-16a ble gjennomgått.	The Board's statement on compensation to leading employees in accordance with the Norwegian Public Limited Companies Act ("the Act") section 6-16a was discussed.
Følgende vedtak ble fattet:	The following resolution was passed:
Del 1:	Part 1:
"Generalforsamlingen gir sin tilslutning til styrets erklæring om lønn og annen godtgjørelse til ledende ansatte."	"The General Meeting supports the statement of the Board regarding compensation to leading employees."
Del 2:	Part 2:
"Generalforsamlingen godkjenner styrets erklæring om aksjebaserte insentivordninger."	"The General Meeting adopts the statement of the Board regarding share based incentive plans."
8. Valg av medlemmer til styret	8. Election of members to the board of directors
Følgende vedtak ble fattet:	The following resolution was passed:
"Følgende velges som medlemmer av styret for en periode på 2 (to) år, frem til den ordinære generalforsamling 2022:	"The Election Committee proposes that the following are elected as members of the board of directors for a period of 2 (two) years, until the annual general meeting 2022:
Bettina Banoun (gjenvalgt) Espen Marcussen (ny)	Bettina Banoun (re-elected) Espen Marcussen (new)
Styret består da av følgende aksjonærvalgte medlemmer:	The Board consists of the following shareholder elected members:
Ole Enger (leder) $\bullet$	Ole Enger (Chairman) $\bullet$
Bettina Banoun	Bettina Banoun
Mimi K. Berdal	Mimi K. Berdal
Espen Marcussen Øystein Stray Spetalen"	Espen Marcussen Øystein Stray Spetalen"

9. Fullmakt til å utstede aksjer	9. Authorization to issue shares
Følgende vedtak ble truffet:	The following resolution was passed:
"Styret gis fullmakt til å øke aksjekapitalen med inntil NOK 8 868 918 gjennom én eller flere aksjekapitalutvidelser.	"The Board is granted authorization to increase the share capital with up to NOK 8 868 918, through one or several share capital increases.
Fullmakten skal kunne anvendes for følgende formål:	The authorization may be used for one or more of the following purposes:
for å gi Selskapet finansiell fleksibilitet, (i) herunder ved investeringer, oppkjøp og fusjoner.	(i) to provide the Company with financial flexibility, including in connection with investments, mergers and acquisitions.
Pris og tegningsvilkår fastsettes av styret ved hver utstedelse under hensyn til Selskapets behov og aksjenes markedsverdi på det aktuelle tidspunkt. Aksjer vil kunne utstedes mot kontantvederlag eller vederlag i form av andre aktiva (tingsinnskudd).	Price and conditions for subscription will be determined by the Board on issuance, according to the Company's needs and the shares' market value at the time. Shares may be issued in exchange for cash settlement or contribution in kind.
Eksisterende aksjonærers fortrinnsrett til å tegne aksjer vil kunne bli fraveket av styret i forbindelse med utøvelse av fullmakten.	The existing shareholders pre-emptive rights to subscribe shares can be deviated from in connection with the effectuation of this authorization.
Denne fullmakt utløper på datoen for den ordinære generalforsamlingen i 2021, men skal i alle tilfelle utløpe senest 15 måneder fra datoen for denne generalforsamlingen.	The Board's authorization is valid until the Annual General Meeting in 2021, but shall in any event expire at the latest 15 months from the date of this annual general meeting. The Board is at the same time given authorization to make
Styret gis samtidig fullmakt til å foreta nødvendige vedtektsendringer ved utøvelse av fullmakten."	the necessary amendments to the articles of association on execution of the authorization."
10. Fullmakt til å erverve egne aksjer	10. Authorization to acquire treasury shares
Følgende vedtak ble fattet:	The following resolution was passed:
"Styret gis fullmakt til på Selskapets vegne å erverve aksjer i Vistin Pharma ASA til ett eller flere av følgende formål:	"The Board is granted authorization to acquire shares in Vistin Pharma ASA on behalf of the Company for one or more of the following purposes:
for å øke aksjonærenes avkastning. (i)	to increase return on investment for the (i) Company's shareholders.
Fullmakten gjelder for kjøp av inntil 10 % av pålydende av Selskapets aksjekapital, jf. allmennaksjeloven §§ 9-2 og 9- 3. Aksjer kan erverves til minst NOK 1,00 per aksje og maksimalt NOK 100 per aksje. Disse begrensninger skal justeres tilsvarende i tilfelle av aksjespleis, aksjesplitt og lignende transaksjoner. Aksjene skal erverves ved ordinær	The authorization covers purchase(s) of up to 10% of the face value of the share capital of the Company, cf. the public limited liability companies act §§ 9-2 and 9-3. Shares may be acquired at minimum NOK 1 per share and maximum NOK 100 per share. These limitations shall be adjusted in the event of share consolidation, share splits,

and similar transactions. The shares shall be acquired omsetning over børs. through ordinary purchase on the stock exchange. Styrets fullmakt gjelder frem til den ordinære generalforsamlingen i 2021, men skal i alle tilfelle utløpe The Board's authorization is valid until the annual general meeting in 2021, but shall in any event expire at the latest senest 15 måneder fra datoen for denne 15 months from the date of this General Meeting. The generalforsamlingen. Beslutningen skal meldes til og decision shall be notified to and registered by the registreres av Foretaksregisteret innen aksjer erverves i henhold til fullmakten." Norwegian Register of Business Enterprises prior to acquiring any shares pursuant to this authorization." Da det ikke forelå flere saker til behandling, takket As there were no further matters on the agenda, the Chairman thanked the present shareholders for their møteleder for oppmøtet, og møtet ble hevet. participation, and the meeting was adjourned.

Vedlagt følger en detaljert oversikt over utfallet av avstemningene, herunder blant annet antall stemmer for og mot de respektive beslutningene, jf allmennaksjeloven § 5-16.	Attached is a detailed overview of the results and voting, including i.a number of votes for and against the respective resolutions, cf the Norwegian public limited companies act section 5-16.
*	*
Signatur følger på neste side.	The signature follows on the next page.

* These minutes are prepared in Norwegian, with an
English office translation. In case of discrepancies
between the two versions, the Norwegian version shall
prevail.

$\alpha$ .

Signature page for Vistin Pharma ASA Annual General Meeting 2020

Oslo, 19. mai 2020/ Oslo, May 19, 2020

Ali Lugu Alecor LKM

Total Represented

ISIN: NO0010734122 VISTIN PHARMA ASA General meeting date: 19/05/2020 13.00 Today: 19.05.2020

Number of persons with voting rights represented/attended: 2

	Number of shares % sc
Total shares	44,344,592
- own shares of the company	0
Total shares with voting rights	44,344,592
Represented by advance vote	268,074	0.61%
Sum own shares	268,074	0.61%
Represented by proxy	8,630,750	19.46 %
Represented by voting instruction	2,686,572	6.06%
Sum proxy shares	11,317,322 25.52 %
Total represented with voting rights	11,585,396 26.13 %
Total represented by share capital	11,585,396 26.13 %

Registrar for the company:

Signature company:

NORDEA BANK ABP, FILIAL NORGE

VISTIN PHARMA ASA

Protocol for general meeting VISTIN PHARMA ASA

ISIN:	NO0010734122 VISTIN PHARMA ASA
General meeting date: 19/05/2020 13.00
Today:	19.05.2020
Shares class	FOR		Against Abstain Poll in			Poll not registered Represented shares with voting rights
Agenda item 2 Election of the chairman of the meeting and a person to co-sign the minutes
Ordinær	11,585,396	0	0	11,585,396	0	11,585,396
votes cast in %	100.00 %	0.00%	0.00%
representation of sc in %	100.00 %	0.00%	0.00%	100.00 %	0.00%
total sc in %	26.13 %	0.00%	0.00%	26.13 %	0.00%
Total	11,585,396	$\mathbf{o}$		0 11,585,396	о	11,585,396
Agenda item 3 Approval of the notice of the meeting and the agenda
Ordinær	11,585,396	0	0	11,585,396	0	11,585,396
votes cast in %	100.00 %	0.00%	0.00%
representation of sc in %	100.00 %	0.00%	0.00%	100.00 %	0.00%
total sc in %	26.13 %	0.00%	0.00%	26.13 %	0.00%
Total	11,585,396	0		0 11,585,396	0	11,585,396
Agenda item 4 Approval of the annual financial statements and the Directors `report for 2019
Ordinær	11,585,396	0	0	11,585,396	$\mathbf 0$	11,585,396
votes cast in %	100.00 %	$0.00 \%$	0.00%
representation of sc in %	100.00 %	0.00%	0.00%	100.00 %	0.00%
total sc in %	26.13 %	$0.00 \%$	0.00%	26.13 %	0.00%
Total	11,585,396	$\sim$ $\sim$ 0		0 11,585,396	O	11,585,396
Agenda item 5 Approval of remuneration for the Board of Directors and Election Committee
Ordinær	11,582,076	0	3,320	11,585,396	0	11,585,396
votes cast in %	99.97 %	0.00%	0.03%
representation of sc in %	99.97 %	$0.00 \%$	0.03%	100.00 %	0.00%
total sc in %	26.12 %	0.00%	0.01%	26.13 %	0.00%
Total	11,582,076	0		3,320 11,585,396	o	11,585,396
Agenda item 6 Approval of auditor's remuneration
Ordinær	11,585,396	0	0	11,585,396	0	11,585,396
votes cast in %	100.00 %	0.00%	0.00%
representation of sc in %	100.00 %	0.00%	$0.00 \%$	100.00 %	0.00%
total sc in %	26.13 %	$0.00 \%$	0.00%	26.13 %	0.00%
Total	11,585,396	0		0 11,585,396	0	11,585,396
Agenda item 7.1 The General Meeting supports the statement of the Board regarding compensation to
leading employees
Ordinær	11,582,076	0	3,320	11,585,396	0	11,585,396
votes cast in %	99.97 %	0.00%	0.03%
representation of sc in %	99.97 %	0.00%	0.03%	100.00 %	0.00 %
total sc in %	26.12 %	0.00%	0.01%	26.13 %	$0.00 \%$
Total	11,582,076	0		3,320 11,585,396	0	11,585,396

Agenda item 7.2 The General Meeting adopts the statement of the Board regarding long term incentive plans and measures for keeping key personnel

Shares class	FOR		Against Abstain Poll in			Poll not registered Represented shares with voting rights
Ordinær	11,582,076	3,320	0	11,585,396	0	11,585,396
votes cast in %	99.97 %	0.03%	$0.00 \%$
representation of sc in %	99.97 %	0.03%	0.00%	100.00 %	0.00%
total sc in %	26.12 %	0.01%	$0.00 \%$	26.13 %	0.00%
Total	11,582,076	3,320		0 11,585,396	$\mathbf 0$	11,585,396
Agenda item 8 Election of members to the Board of Directors
Ordinær	11,582,076	0	3,320	11,585,396	$\mathbf 0$	11,585,396
votes cast in %	99.97 %	0.00%	0.03%
representation of sc in %	99.97 %	0.00%	0.03%	100.00 %	0.00%
total sc in %	26.12 %	0.00%	0.01%	26.13 %	0.00%
Total	11,582,076	$\mathbf{o}$		3,320 11,585,396	$\mathbf 0$	11,585,396
Agenda item 9 Authorisation to issue shares
Ordinær	11,585,396	0	$\mathbf 0$	11,585,396	$\mathbf 0$	11,585,396
votes cast in %	100.00 %	0.00%	0.00%
representation of sc in %	100.00 %	$0.00 \%$	0.00%	100.00 %	0.00%
total sc in %	26.13 %	0.00%	0.00%	26.13 %	0.00%
Total	11,585,396	0		0 11,585,396	$\mathbf 0$	11,585,396
Agenda item 10 Authorisation to acquire treasury shares
Ordinær	11,585,396	0	0	11,585,396	0	11,585,396
votes cast in %	100.00 %	0.00%	0.00%
representation of sc in %	100.00 %	$0.00 \%$	0.00%	100.00 %	0.00%
total sc in %	26.13 %	$0.00 \%$	$0.00 \%$	26.13 %	0.00%
Total	11,585,396	0		0 11,585,396	$\mathbf o$	11,585,396

Registrar for the company:

Signature company:

NORDEA BANK ABP, FILIAL NORGE

VISTIN PHARMA ASA

Share information

Name	Total number of shares Nominal value Share capital Voting rights
Ordinær	44,344,592	1.00 44,344,592.00 Yes
Sum:

§ 5-17 Generally majority requirement
requires majority of the given votes

§ 5-18 Amendment to resolution
Requires two-thirds majority of the given votes
like the issued share capital represented/attended on the general meeting